Epidemiology of Parkinson's disease

Handbook of Clinical Neurology

Volumn 83, Issue , 2007, Pages 129-151

  Kasten, Meike ^a   Chade, Annabel ^a   Tanner, Caroline M ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649348452     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)83006-5     Document Type: Review

References (266)

1. Abbott R.D., Petrovitch H., White L.R., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 (2001) 456-462
2. Abbott R.D., Ross G.W., White L.R., et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 59 (2002) 1051-1057
3. Abbott R.D., Ross G.W., White L.R., et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 250 Suppl 3 (2003) 30-39
4. Acosta J., Calderon E., and Obeso J.A. Prevalence of Parkinson's disease and essential tremor in a village in southern Spain. Neurology 39 Suppl 1 (1989) 181
5. Alves G., Kurz M., Lie S.A., et al. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord 19 (2004) 1087-1092
6. Anca M., Paleacu D., Shabtai H., et al. Cross-sectional study of the prevalence of Parkinson's Disease in the Kibbutz Movement in Israel. Neuroepidemiology 21 (2002) 50-55
7. Anderson D.W., Rocca W.A., de Rijk M.C., et al. Case ascertainment uncertainties in prevalence surveys of Parkinson's Disease. Mov Disord 13 (1998) 626-632
8. Ascherio A., Zhang S.M., Hernan M.A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50 (2001) 56-63
9. Ascherio A., Chen H., Schwarzschild M.A., et al. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 5 (2003) 790-795
10. Ascherio A., Weisskopf M.G., O'Reilly E.J., et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160 10 (2004) 977-984
11. Ascherio A., Weisskopf M.G., and Chen H. Uricemia and risk of Parkison's disease. Neurology 66 5 Suppl 4 (2006) A382
12. Ashok P.P., Radhakrishnan K., Sridharan R., et al. Parkinsonism in Benghazi, East Libya. Clin Neurol Neurosurg 88 (1986) 109-113
13. Baldereschi M., Di Carlo A., Rocca W.A., et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55 (2000) 1358-1363
14. Benamer H.T., Oertel W.H., Patterson J., et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 18 (2003) 977-984
15. Benedetti M.D., Bower J.H., Maraganore D.M., et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55 (2000) 1350-1358
16. Benedetti M.D., Maraganore D.M., Bower J.H., et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 16 5 (2001) 830-837
17. Berg D., Roggendorf W., Schroder U., et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59 (2002) 999-1005
18. Bernheimer H., Birkmayer W., Hornykiewicz O., et al. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973) 415-455
19. Bertram L., and Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J Clin Invest 115 (2005) 1449-1457
20. Bharucha N.E., Stokes L., Schoenberg B.S., et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology 36 (1986) 284-288
21. Bharucha N.E., Bharucha E.P., Bharucha A.E., et al. revalence of Parkinson's disease in the Parsi community of Bombay, India. Arch Neurol 45 (1988) 1321-1323
22. Boka G., Anglade P., Wallach D., et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172 1-2 (1994) 151-154
23. Bonifati V., Fabrizio E., Vanacore N., et al. Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci 22 4 (1995) 272-279
24. Bonifati V., Rizzu P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
25. Bonifati V., Rohe C.F., Breedveld G.J., et al. Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65 1 (2005) 87-95
26. Bower J.H., Maraganore D.M., McDonnell S.K., et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52 (1999) 1214-1220
27. Bower J.H., Maraganore D.M., McDonnell S.K., et al. Influence of strict, intermediate, and broad diagnostic criteria on the age and sex-specific incidence of Parkinson's disease. Mov Disord 15 (2000) 819-825
28. Bower J.H., Maraganore D.M., Peterson B.J., et al. Head trauma preceding PD: a case-control study. Neurology 60 (2003) 1610-1615
29. Braak H., Rub U., Gai W.P., et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110 5 (2003) 517-536
30. Braak H., Del Tredici K., Rub U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 2 (2003) 197-211
31. Braak H., Ghebremedhin E., Rub U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 1 (2004) 121-134 [Epub 2004 Aug 24]
32. Breitner J.C., and Zandi P.P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?. N Engl J Med 345 21 (2001) 1567-1568
33. Brewis M., Poskanzer D.C., Rolland C., et al. Neurological disease in an English city. Acta Neurol Scand 42 Suppl 24 (1966) 9-89
34. Bronstein D.M., Perez-Otano I., Sun V., et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704 1 (1995) 112-116
35. Butterfield P.G., Valanis B.G., Spencer P.S., et al. nvironmental antecedents of young-onset Parkinson's disease. Neurology 43 6 (1993) 1150-1158
36. Caradoc-Davies T.H., Weatherall M., Dixon G.S., et al. s the prevalence of Parkinson's disease in New Zealand really changing?. Acta Neurol Scand 86 (1992) 40-44
37. Castano A., Herrera A.J., Cano J., et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81 1 (2002) 150-157
38. Cerhan J.R., Wallace R.B., and Folsom A.R. Antioxidant intake and risk of Parkinson's disease (PD) in older women. Am J Epidemiol 139 (1994) S65
39. Chalmanov V.N. Epidemiological studies of parkinsonism in Sofia. Neuroepidemiology 5 (1986) 171-177
40. Champy P., Melot A., Guerineau Eng V., et al. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe. Mov Disord 20 12 (2005) 1629-1633
41. Chan D.K., Cordato D., Karr M., et al. Prevalence of Parkinson's disease in Sydney. Acta Neurol Scand 111 (2005) 7-11
42. Checkoway H., Franklin G.M., Costa-Mallen P., et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology 50 (1998) 1458-1461
43. Checkoway H., and Nelson L. Epidemiologic approaches to the study of Parkinson's Disease etiology. Epidemiology 10 3 (1999) 327-336
44. Chen H., Steyn S., Staal R., et al. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277 39 (2002) 36040-36044 Epub 2002 Jul 18
45. Chen H., Zhang S.M., Hernan M.A., et al. Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol 52 (2002) 793-801
46. Chen H., Zhang S.M., Hernan M.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
47. Chen H., Zhang S.M., Schwarzschild M.A., et al. Folate intake and risk of Parkinson's disease. Am J Epidemiol 160 4 (2004) 368-375
48. Chen H., Zhang S.M., Schwarzschild M.A., et al. Obesity and the risk of Parkinson's disease. Am J Epidemiol 159 6 (2004) 547-555
49. Chen H., Zhang S.M., Schwarzschild M.A., et al. Physical activity and the risk of Parkinson disease. Neurology 64 4 (2005) 664-669
50. Chen H., Jacobs E., Schwarzschild M.A., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58 6 (2005) 963-967
51. Chen H., Zhang S.M., Schwarzschild M.A., et al. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 21 7 (2006) 1002-1007 [Epub ahead of print]
52. Chu I., Villeneuve D.C., Yagminas A., et al. Toxicity of 2,2′,4,4′,5,5′-hexachlorobiphenyl in rats: effects following a 90-day oral exposure. J Appl Toxicol 16 2 (1996) 121-128
53. Coggon D., Inskip H., Winter P., et al. Occupational mortality by cause of death. In: Drever F. (Ed). Occupational Health Decennial Supplement (1995), Her Majesty's Stationery Office, London 62-76
54. Cohen A.D., Tillerson J.L., Smith A.D., et al. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85 2 (2003) 299-305
55. Corrigan F.M., Murray L., Wyatt C.L., et al. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 150 2 (1998) 339-342
56. Currie L.J., Harrison M.B., Trugman J.M., et al. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61 6 (2004) 886-888
57. Davis J.W., Grandinetti A., Waslien C.I., et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144 5 (1996) 480-484
58. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkisnon's disease. Science 302 (2003) 819-822
59. Deguchi K., Sasaki I., Tsukaguchi M., et al. Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 199 1-2 (2002) 31-37
60. de Lau L.M., Giesbergen P.C., de Rijk M.C., et al. ncidence of parkinsonism and Parkinson disease in a general population. The Rotterdam Study. Neurology 63 (2004) 1240-1244
61. De Michele G., Filla A., Volpe G., et al. Environmental and genetic risk factors in Parkinson's disease: a case- control study in Southern Italy. Mov Disord 11 1 (1996) 17-23
62. De Reuck J., De Weweire M., Van Maele G., et al. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. J Neurol Sci 231 1-2 (2005) 35-39
63. Dewailly E., Mulvad G., Pedersen H.S., et al. Concentration of organochlorines in human brain, liver, and adipose tissue autopsy samples from Greenland. Environ Health Perspect 107 10 (1999) 823-828
64. DiMonte D.A. The environment and parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol 2 (2003) 531-538
65. Di Rocco A., Molinari S.P., Kollmeier B., et al. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 69 (1996) 3-11
66. Doll R., Peto R., Wheatley K., et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 309 (1994) 901-911
67. Duan W., Ladenheim B., Cutler R.G., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80 1 (2002) 101-110
68. Duarte J., Claveria L.E., de Pedro-Cuesta J., et al. creening Parkinson's disease: a validated questionnaire of high specificity and sensitivity. Mov Disord 10 (1995) 643-649
69. Duvoisin R.C., Eldridge R., Williams A., et al. Twin study of Parkinson disease. Neurology 31 (1981) 77-80
70. Elbaz A., Manubens-Bertran J.M., Baldereschi M., et al. Parkinson's disease, smoking, and family history. EUROPARKINSON Study Group. J Neurol 247 10 (2000) 793-798
71. Elbaz A., McDonnell S.K., Maraganore D.M., et al. Validity of family history data on PD: evidence for a family information bias. Neurology 61 1 (2003) 11-17
72. Elbaz A., Bower J.H., Peterson B.J., et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60 1 (2003) 91-96
73. Elbaz A., Levecque C., Clavel J., et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 55 (2004) 430-434
74. Factor S.A., and Weiner W.J. Prior history of head trauma in Parkinson's disease. Mov Disord 6 (1991) 225-229
75. Fall P.A., Axelson O., Fredriksson M., et al. Age- standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 49 6 (1996) 637-641
76. Fall P.A., Fredrikson M., Axelson O., et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 14 (1999) 28-37
77. Fall P.A., Saleh A., Fredrickson M., et al. Survival time, mortality and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 18 (2003) 1312-1316
78. Fazzini E., Fleming J., and Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 7 2 (1992) 153-158
79. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
80. Ferger B., Spratt C., Earl C.D., et al. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 351-359
81. Ferger B., Teismann P., Earl C.D., et al. Salicylate protects against MPTP-induced motor impairments in the dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360 3 (1999) 256-261
82. Ferraz H.B., Andrade L.A., Tumas V., et al. Rural or urban living and Parkinson's disease. Arq Neuropsiquiatr 54 1 (1996) 37-41
83. Fertl E., Doppelbauer A., and Auff E. Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors. J Neural Transm Park Dis Dement Sect 5 2 (1993) 157-161
84. Firestone J.A., Smith-Weller T., Franklin G., et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 62 (2005) 91-95
85. Fored C.M., Fryzek J.P., Brandt L., et al. Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup Environ Med 63 2 (2006) 135-140
86. Fowler J.S., Volkow N.D., Wang G.J., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 (1996) 733-736
87. Fryzek J.P., Hansen J., Cohen S., et al. A cohort study of Parkinson's disease and other neurodegenerative disorders in Danish welders. J Occup Environ Med 47 (2005) 466-472
88. Galanaud J.P., Elbaz A., Clavel J., et al. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord 20 2 (2005) 181-189
89. Gale C.R., Martyn C.N., Winter P.D., et al. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 310 (1995) 1563-1566
90. Gao H.M., Jiang J., Wilson B., et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81 6 (2002) 1285-1297
91. Gibb W.R., and Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54 5 (1991) 388-396
92. Gibberd F.B., and Simmonds J.P. Neurological disease in ex-Far-East prisoners of war. Lancet 2 8186 (1980) 135-137
93. Giroud Benitez J.L., Collado-Mesa F., and Esteban E.M. Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba. Door-to-door population study. Neurologia 15 7 (2000) 269-273
94. Granieri E., Carreras M., Casetta I., et al. Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol 48 (1991) 854-857
95. Goldman S.M., Tanner C.M., Oakes D., et al. Head injury and Parkinson's disease risk in twins. Ann Neurol 60 1 (2006) 65-72
96. Gorell J.M., Johnson C.C., Rybicki B.A., et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 5 (1998) 1346-1350
97. Gorell J.M., Peterson E.L., Rybicki B.A., et al. Multiple risk factors for Parkinson's disease. J Neurol Sci 217 (2004) 169-174
98. Grandinetti A., Morens D.M., Reed D., et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 139 (1994) 1129-1138
99. Gudmundsson K.R. A clinical survey of parkinsonism in Iceland. Acta Neurol Scand 43 Suppl 33 (1967) 1-61
100. Haack D.G., Baumann R.J., McKean H.E., et al. Nicotine exposure and Parkinson disease. Am J Epidemiol 114 2 (1981) 191-200
101. Harada H., Nishikawa S., and Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 40 (1983) 151-154
102. Hattori N., Kitada T., Matsumine H., et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 44 (1998) 935-941
103. Hauser R.A., Zesiewicz T.A., Rosemurgy A.S., et al. Manganese intoxication and chronic liver failure. Ann Neurol 36 6 (1994) 871-875
104. Hauser R.A., Hubble J.P., and Truong D.D. Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 3 (2003) 297-303
105. Hellenbrand W., Boeing H., Robra B.P., et al. Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47 (1996) 644-650
106. Hely M.A., Morris J.G., Traficante R., et al. The Sidney Multicentre Study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67 (1999) 300-307
107. Hernan M.A., Takkouche B., Caamano-Isorna F., et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 (2002) 276-284
108. Hernan M.A., Checkoway H., O'Brien R., et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 58 9 (2002) 1381-1387
109. Hernan M.A., Chen H., Schwarzschild M.A., et al. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol 54 2 (2003) 170-175
110. Hernan M.A., Logroscino G., and Rodriguez L.A. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 251 Suppl 7 (2004) 14-17 vII
111. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 7 (2006) 1097-1099
112. Herrera A.J., Castano A., Venero J.L., et al. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7 4 (2000) 429-447
113. Hirsch E.C., Breidert T., Rousselet E., et al. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991 (2003) 214-228
114. Hobson P., Gallacher J., and Meara J. Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom. Mov Disord 20 8 (2005) 995-998
115. Hubble J.P., Cao T., Hassanein R.E., et al. Risk factors for Parkinson's disease. Neurology 43 9 (1993) 1693-1697
116. Hubble J.P., Venkatesh R., Hassanein R.E., et al. Personality and depression in Parkinson's disease. J Nerv Ment Dis 181 11 (1993) 657-662
117. Hubble J.P., Cao T., Kjelstrom J.A., et al. Nocardia species as an etiologic agent in Parkinson's disease: serological testing in a case-control study. J Clin Microbiol 33 10 (1995) 2768-2769
118. Hughes A.J., Daniel S.E., Blankson S., et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50 (1993) 140-148
119. Hughes A.J., Daniel S.E., and Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (2001) 1497-1499
120. Hughes A.J., Daniel S.E., Ben Shlomo Y., et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 Part 4 (2002) 861-870
121. Hunot S., Dugas N., Faucheux B., et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19 9 (1999) 3440-3447
122. in t' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 21 (2001) 1515-1521
123. Janson A.M., and Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57 (1993) 931-941
124. Jenkins A.C. Epidemiology of parkinsonism in Victoria. Med J Aust 2 (1966) 497-502
125. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61 11 Suppl 6 (2003) S32-S38
126. Kanda T., Tashiro T., Kuwana Y., et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9 12 (1998) 2857-2860
127. Kaur D., Yantiri F., Rajagopalan S., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 6 (2003) 899-909
128. Kay D.M., Zabetian C.P., Factor S.A., et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 21 4 (2006) 519-523 [Epub ahead of print]
129. Kessler II. Epidemiologic studies of Parkinson's disease. II. A hospital-based survey. Am J Epidemiol 95 4 (1972) 308-318
130. Kessler II. Epidemiologic studies of Parkinson's disease. III. A community-based survey. Am J Epidemiol 96 4 (1972) 242-254
131. Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
132. Kobbata S., and Beaman B.L. L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 59 1 (1991) 181-191
133. Korell M., and Tanner C.M. Epidemiology of Parkinson's Disease: an overview. In: Ebadi M., and Pfeiffer R.F. (Eds). Parkinson's Disease (2005), CRC Press, New York 39-50
134. Knekt P., Reunanen A., Järvinen R., et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 139 (1994) 1180-1189
135. Knekt P., Järvinen R., Reunanen A., et al. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 312 (1996) 478-481
136. Kumar A., Calne S.M., Schulzer M., et al. Clustering of Parkinson disease: shared cause or coincidence?. Arch Neurol 61 7 (2004) 1057-1060
137. Kuopio A.M., Marttila R.J., Helenius H., et al. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 52 (1999) 302-308
138. Kusumi M., Nakashima K., Harada H., et al. Epidemiology of Parkinson's disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology 15 4 (1996) 201-207
139. Kurland L.T. Epidemiology. Incidence, geographic distribution and genetic considerations. In: Field W. (Ed). Pathogenesis and Treatment of Parkinsonism (1958), Charles C. Thomas, Springfield 5-43
140. Kwok J.B., Hallupp M., Loy C.T., et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58 6 (2005) 829-839
141. Lan J., and Jiang D.H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104 6-7 (1997) 649-660
142. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 4587 (1983) 979-980
143. Langston J.W., Forno L.S., Tetrud J., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 4 (1999) 598-605
144. Le W.D., Xu P., Jankovic J., et al. Mutations in NR4A2 associated with familial Parkinson's disease. Nat Genet 33 (2003) 85-89
145. Lees A.J., Katzenschlager R., Head J., et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57 (2001) 1687-1694
146. Leroy E., Boyer R., Auburger G., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
147. Lesage S., Ibanez P., Lohmann E., et al. French Parkinson's Disease Genetics Study Group G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58 5 (2005) 784-787
148. Levy G., Tang M.X., Cote L.J., et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 17 2 (2002) 250-257
149. Li S.C., Schoenberg B.S., Wang C.C., et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 42 (1985) 655-657
150. Lilienfeld D.E., Sekkor D., Simpson S., et al. Parkinsonism death rates by race, sex and geography: a 1980s update. Neuroepidemiology 9 5 (1990) 243-247
151. Louis E.D., Marder K., Cote L., et al. Mortality from Parkinson's disease. Arch Neurol 54 3 (1997) 260-264
152. MacDonald B.K., Cockerell O.C., Sander J.W., et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123 Pt 4 (2000) 665-676
153. Maggio R., Riva M., Vaglini F., et al. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J Neural Transm 104 (1997) 1113-1123
154. Maher N.E., Golbe L.I., Lazzarini A.M., et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology 58 1 (2002) 79-84
155. Maraganore D.M., Anderson D.W., Bower J.H., et al. Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minesota. Neurology 53 6 (1999) 1342-1344
156. Marder K., Tang M.X., Mejia H., et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 47 (1996) 155-160
157. Marder K., Logroscino G., Alfaro B., et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 50 1 (1998) 279-281
158. Marek K.L., Seibyl J.P., Zoghbi S.S., et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 (1996) 231-237
159. Marras C., and Tanner C.M. Epidemiology of Parkinson's Disease. In: Watts R.L., and Koller W.C. (Eds). Movement Disorders, Neurologic Principles and Practice (2002), McGraw-Hill, New York 117-195
160. Marras C., Goldman S., Smith A., et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord 20 6 (2005) 687-693
161. Marras C., McDermott M.P., Rochon P.A., et al. Parkinson Study Group. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64 1 (2005) 87-93
162. Marsden C.D. Twins and Parkinson's disease. J Neurol Neurosurg Psychiatry 50 (1987) 105-106
163. Marttila R.J., and Rinne U.K. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 43 Suppl 33 (1967) 9-61
164. Marttila R.J., Arstila P., Nikoskelainen J., et al. Viral antibodies in the sera from patients with Parkinson's disease. Eur Neurol 15 (1977) 25-33
165. Marttila R.J., Kaprio J., Koshewvuo M., et al. Parkinson's disease in a nationwide twin cohort. Neurology 38 (1988) 1217-1219
166. Mars U., and Larsson B.S. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 12 4 (1999) 266-274
167. Mayeux R., Denaro J., Hemenegildo N., et al. A population-based investigation of Parkinson's disease with and without dementia: relationships to age and gender. Arch Neurol 42 (1992) 492-497
168. Mayeux R., Marder K., Cote L.J., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 142 (1995) 820-827
169. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035 (2004) 104-116
170. McGeer P.L., Itagaki S., Akiyama H., et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24 (1988) 574-576
171. Menegon A., Board P.G., Blackburn A.C., et al. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 9137 (1998) 1344-1346
172. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2 (2000) 421-426
173. Morano A., Jimenez-Jimenez F.J., Molina J.A., et al. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand 89 3 (1994) 164-170
174. Morens D.M., Davis J.W., Grandinetti A., et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 46 (1996) 1044-1050
175. Morens D.M., Grandinetti A., Davis J.W., et al. Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Am J Epidemiol 144 4 (1996) 400-404
176. Morgante L., Rocca W.A., Di Rosa A.E., et al. Prevalence of Parkinson's disease and other parkinsonisms: a door-to-door survey in three Sicilian municipalities. Neurology 42 (1992) 1901-1907
177. Morgante L., Salemi G., Meneghini F., et al. Parkinson disease survival: a population-based study. Arch Neurol 57 4 (2000) 507-512
178. Murch S.J., Cox P.A., and Banack S.A. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci USA 101 33 (2004) 12228-12231 [Epub 2004 Aug 4]
179. Mutch W.J., Dingwall-Fordyce I., Downie A.W., et al. Parkinson's disease in a Scottish city. BMJ (1986) 534-536
180. Mutch W.J., Smith W.C., and Scott R.F. A screening and alerting questionnaire for parkinsonism. Neuroepidemiology 10 (1991) 150-156
181. Nagatsu T., Mogi M., Ichinose H., et al. Cytokines in Parkinson's disease. J Neural Transm Suppl 58 (2000) 143-151
182. Nehlig A., Daval J.L., and Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical,metabolic and psychostimulant effects. Brain Res Brain Res Rev 17 2 (1992) 139-170
183. Nelson L., Van Den Eeden S., and Tanner C. Association of alcohol and tobacco consumption with Parkinson's disease: a population-based study. Neurology 52 (1999) A538-A539
184. Nishitani H., Kuno A., Konishi T., et al. Epidemiological study of Parkinson's disease: area survey and the follow-up study. Annual Report of the Research Committee of Degenerative Disorders. The Ministry of Health and Welfare of Japan 3 (1981), Government Press, Tokyo 81-86
185. Okada K., Kobayashi S., and Tsunematsu T. Prevalence of Parkinson's disease in Izumo City, Japan. Gerontology 36 (1990) 340-344
186. O'Reilly E.J., McCullough M.L., Chao A., et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 20 10 (2005) 1383-1384
187. O'Suilleabhain P.E., Sung V., Hernandez C., et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61 6 (2004) 865-868
188. Ozelius L.J., Senthil G., Saunders-Pullman R., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews [letter]. N Engl J Med 354 4 (2006) 424-425
189. Paganini-Hill A. Risk factors for parkinson's disease: the leisure world cohort study. Neuroepidemiology 20 (2001) 118-124
190. Page W.F., and Tanner C.M. Parkinson's disease and motor-neuron disease in former prisoners-of-war. Lancet 355 9206 (2000) 843
191. Paisan-Ruiz C., Jain S., Evans E.W., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
192. Papapetropoulos S., Singer C., Villar J.M., et al. Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson's disease?. Mov Disord 20 5 (2005) 641-642
193. Park M., Ross G.W., Petrovitch H., et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64 6 (2005) 1047-1051
194. Parkinson J. An Essay on the Shaking Palsy. Sherwood (1817), Neely and Jones, London
195. Payami H., Larsen K., Bernard S., et al. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 36 (1994) 659-661
196. Polymeropoulos M.H., Higgins J.J., Golbe L.I., et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274 (1996) 1197-1199
197. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in tha alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
198. Popat R.A., Van Den Eeden S.K., Tanner C.M., et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65 3 (2005) 383-390
199. Popoli P., Caporali M.G., and Scotti de Carolis A. Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility. J Pharm Pharmacol 43 4 (1991) 280-281
200. Powers K.M., Smith-Weller T., Franklin G.M., et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60 11 (2003) 1761-1766
201. Prasad C., Ikegami H., Shimizu I., et al. Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons. Life Sci 54 (1994) 1169-1184
202. Pressley J., Tang M., Marder K., et al. Disparities in the recording of Parkinson's disease on death certificates. Mov Disord 20 3 (2005) 315-321
203. Priyadarshi A., Khuder S.A., Schaub E.A., et al. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 21 (2000) 435-440
204. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 27 (2004) 561-568
205. Racette B.A., Tabbal S.D., Jennings D., et al. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 64 (2005) 230-235
206. Ragonese P., D'Amelio M., Salemi G., et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62 11 (2004) 2010-2014
207. Rajput A.H., Offord K.P., Beard C.M., et al. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16 (1984) 278-282
208. Rajput A.H., Offord K.P., Beard C.M., et al. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 37 2 (1987) 226-232
209. Richardson P.J., Kase H., and Jenner P.G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 18 9 (1997) 338-344
210. Rimm E.B., Stampfer M.J., Ascherio A., et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328 (1993) 1450-1456
211. Rocca W.A., Bower J.H., McDonnell S.K., et al. Time trends in the incidence of parkinsonisms in Olmsted County, Minnesota. Neurology 57 (2001) 462-467
212. Rosati G., Granieri E., Pinna L., et al. The risk of Parkinson's disease in Mediterranean people. Neurology 30 (1980) 250-255
213. Ross G., White L., and Petrovitch H. Lack of association to midlife smoking or coffee consumption with presence of lewy bodies in the locus ceruleus or substantia nigra at autopsy. Neurology 52 Suppl 2 (1999) A539
214. Ross G.W., Abbott R.D., Petrovitch H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
215. Ross G.W., Petrovitch H., Abbott R.D., et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 56 4 (2004) 532-539
216. Sasco A.J., and Paffenbarger Jr. R.S. Measles infection and Parkinson's disease. Am J Epidemiol 122 6 (1985) 1017-1031
217. Sasco A.J., Paffenbarger Jr. R.S., Gendre I., et al. The role of physical exercise in the occurrence of Parkinson's disease. Arch Neurol 49 4 (1992) 360-365
218. Scheider W.L., Hershey L.A., Vena J.E., et al. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord 12 2 (1997) 190-196
219. Schoenberg B.S., Anderson D.W., and Haerer A.F. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 35 (1985) 841-845
220. Schoenberg B.S., Osuntokun B.O., Adeuja A., et al. Comparison of the prevalence of Parkinson's disease in black populations in the rural US and in rural Nigeria: door-to-door community studies. Neurology 38 (1988) 645-646
221. Schulte P.A., Burnett C.A., Boeniger M.F., et al. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am J Public Health 86 9 (1996) 1281-1288
222. Scott W.K., Zhang F., Stajich J.M., et al. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 64 3 (2005) 442-447
223. Seegal R.F., Brosch K.O., and Bush B. Polychlorinated biphenyls produce regional alterations of dopamine metabolism in rat brain. Toxicol Lett 30 (1986) 197-202
224. Seidler A., Hellenbrand W., Robra B.P., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46 (1996) 1275-1284
225. Semchuk K.M., Love E.J., and Lee R.G. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci 18 3 (1991) 279-286
226. Semchuk K.M., Love E., and Lee R. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 43 (1993) 1173-1180
227. Shi Y. Study on the prevalence of Parkinson's disease in Hongkou District, Shanghai. Chinese J Epidemiol 4 (1987) 205-209
228. Siderowf A., Newberg A., Chou K.L., et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64 10 (2005) 1716-1720
229. Spencer P. Guam ALS/Parkinsonism-Dementia: a long-latency neurotoxic disorder caused by "slow toxin(s)" in food?. Can J Neurol Sci 14 (1987) 347-357
230. Stern M.B. Head trauma as a risk factor for Parkinson's disease. Mov Disord 6 2 (1991) 95-97
231. Stewart W.F., and Stewart P.A. Occupational case-control studies: I. Collecting information on work histories and work-related exposures. Am J Ind Med 26 3 (1994) 297-312
232. Stiasny-Kolster K., Doerr Y., Moller J.C., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 Pt 1 (2005) 126-137 [Epub 2004 Nov 17]
233. Sugita M., Izuno T., Tatemichi M., et al. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J Epidemiol 11 (2001) 87-94
234. Sutcliffe R.L., and Meara J.R. Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 92 6 (1995) 443-450
235. Sutcliffe R.L., Prior R., Mawby B., et al. Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. Acta Neurol Scand 72 (1985) 363-379
236. Tan E.K., Chai A., Zhao Y., et al. Mitochondrial complex I polymorphism and cigarette smoking in Parkinson's disease. Neurology 59 8 (2002) 1288-1289
237. Tanner C.M., and Goldman S.M. Epidemiology of movement disorders. Curr Opin Neurol 7 (1994) 340-345
238. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol Clin 14 (1996) 317-335
239. Tanner C.M., Chen B., Wang W.Z., et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 14 3 Suppl (1987) 419-423
240. Tanner C.M., Gilley D.W., and Goetz C.G. A brief screening questionnaire for parkinsonism. Ann Neurol 28 (1990) 267-268
241. Tanner C.M., Thelen J.A., Offord K.P., et al. Parkinson's disease incidence in Olmsted County, MN: 1935 - 1988. Neurology 42 Suppl 3 (1992) 194
242. Tanner C.M., Goldman S.M., Aston D.A., et al. Smoking and Parkinson's disease in twins. Neurology 58 4 (2002) 581-588
243. Tanner C.M., Goldman S.M., and Quinlan P. Occupation and Risk of Parkinson's Disease (PD): a preliminary investigation of standard occupational codes (SOC) in twins discordant for disease. Neurology 60 Suppl 1 (2003) A415
244. Taylor C.A., Saint-Hilaire M.H., Cupples L.A., et al. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am J Med Genet 88 (1999) 742-749
245. Taylor M.C., Le Couteur D.G., Mellick G.D., et al. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 107 8-9 (2000) 979-983
246. Tielemans E., Heederik D., Burdorf A., et al. Assessment of occupational exposures in a general population: comparison of different methods. Occup Environ Med 56 3 (1999) 145-151
247. Tillerson J.L., Caudle W.M., Reveron M.E., et al. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119 3 (2003) 899-911
248. Tsai C.H., Lo S.K., See L.C., et al. Environmental risk factors of young onset Parkinson's disease: a case-control study. Clin Neurol Neurosurg 104 4 (2002) 328-333
249. Tsui J.K., Calne D.B., Wang Y., et al. Occupational risk factors in Parkinson's disease. Can J Public Health 90 (1999) 334-337
250. Twelves D., Persins K., and Counsell. Systematic review of incidence studies of Parkinson's disease. Mov Disord 18 1 (2003) 19-31
251. Van Den Eeden S.K., Tanner C., and Popat R. The risk of Parkinson's disease associated with head injury and depression: a population-based case-control study. Neurology 54 7, Suppl 3 (2000) A347
252. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157 (2003) 1015-1022
253. Vieregge P., Schiffke K.A., Friedrich H.J., et al. Parkinson's disease in twins. Neurology 42 (1992) 1453-1461
254. Wang S.J., Fuh J.L., Liu C.Y., et al. Parkinson's disease in Kin-Hu, Kinmen: a community survey by neurologists. Neuroepidemiology 13 (1994) 69-74
255. Wang W.Z., Fang X.H., Cheng X.M., et al. A case- control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 12 (1993) 209-218
256. Wang Y., and Collaborative Group of Neuroepidemiology of the PLA. The incidence and prevalence of Parkinson's disease in the People's Republic of China. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih. Chinese Journal of Epidemiology 12 (1991) 363-365
257. Wenning G.K., Donnemiller E., Granata R., et al. [123-I]-beta-CIT and [123-I]-IBZM-SPECT scanning in levodopanaive Parkinson's disease. Mov Disord 13 (1998) 438-445
258. Wermuth L., Bunger N., von Weitzel-Mudersback P., et al. Clinical characteristics of Parkinson's disease among Inuit in Greenland and inhabitants of the Faroe Islands and Als (Denmark). Mov Disord 19 7 (2004) 821-824
259. Willems-Giesbergen P., de Rijk M., and van Swieten J. Smoking, alcohol, and coffee consumption and the risk of Parkinson's disease: results from the Rotterdam Study. Neurology 54 (2000) A347
260. Willett W. Overview of nutritional epidemiology. In: Willett W. (Ed). Nutritional Epidemiology. 1st edn. (1990), Oxford University Press, New York/Oxford 3-19
261. Wirdefeldt K., Gatz M., Schalling M., et al. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63 2 (2004) 305-311
262. Wooten G.F., Currie L.J., Bovbjerg V.E., et al. Are men at greater risk for Parkinson's disease than women?. J Neurol Neurosurg Psychiatry 75 4 (2004) 637-639
263. Xu K., Bastia E., and Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 105 3 (2005) 267-310
264. Zhang Z., and Roman G. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208
265. Zimprich A., Biskup S., Leitner P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
266. Zorzon M., Capus L., Pellegrino A., et al. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand 105 2 (2002) 77-82